MAP2K7 and Miyoshi myopathy: Driven by paradoxical reactivation of MEK/ERK pathway downstream of BRAF [39], resistance to targeted therapy was extensively studied in BRAF-mutated MM leading to cellular reprogramming at multiple levels, including metabolism and epigenome organization, promoting a dynamic deregulation of differentiation/mesenchymal/stemness transcriptional programs [18, 19, 40–42].